CompletedPHASE1, PHASE2NCT05030831

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Studying Pseudoxanthoma elasticum

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Inozyme Pharma
Principal Investigator
Kurt Gunter, MD
Inozyme Pharma, Inc.
Intervention
INZ-701(drug)
Enrollment
10 enrolled
Eligibility
18-69 years · All sexes
Timeline
2022 – 2024

Study locations (2)

Collaborators

IQVIA Biotech

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05030831 on ClinicalTrials.gov

Other trials for Pseudoxanthoma elasticum

Additional recruiting or active studies for the same condition.

See all trials for Pseudoxanthoma elasticum →

← Back to all trials